Key result
Increasing evidence-based treatments to cover at least 60% of eligible patients could have prevented approximately 4100 additional coronary heart disease deaths in Sweden in 2002.
Why the study?
Does increasing the use of evidence-based treatments to at least 60% of eligible patients reduce CHD mortality in Sweden?
Population
Patients with coronary heart disease (CHD) and high-risk individuals eligible for primary prevention in Sweden
Comparison
Increasing evidence-based treatments to… vs Baseline scenario
Design
Other
Authors
Loading...
May support scaling evidence-based CHD therapies to cut mortality; leaves open prospective confirmation in current populations.
Does increasing the use of evidence-based treatments to at least 60% of eligible patients reduce CHD mortality in Sweden?
Effect estimate: 4100 fewer deaths
Increasing the uptake of evidence-based treatments for CHD and primary prevention to at least 60% of eligible patients could substantially reduce CHD mortality.
Björck et al. (2010) studied Coronary heart disease. Increasing evidence-based treatments to ≥60% coverage vs. Actual treatment levels in 2002 (baseline scenario) was evaluated on Number of deaths prevented or postponed (4100 fewer deaths). Increasing evidence-based treatments to cover at least 60% of eligible patients could have prevented approximately 4100 additional coronary heart disease deaths in Sweden in 2002.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: